Nama Insights

Baxter International (BAX)

Healthcare · Medical Instruments Supplies · NYSE

S&P 500
Baxter International (BAX) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $13.34B, a trailing price-to-earnings ratio of 13.3 and a free-cash-flow yield of 2.4%. Over the most recent reported fiscal year, revenue grew 5.7% and free cash flow per share fell 42.6%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Rising · +33.3% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-71.2%
How far the last close sits under the highest price of the past five years.
Market cap$13.34B
Trailing P/E13.3
Price / book2.1
Price / sales1.1
FCF yield2.4%
Dividend yield0.2%
Gross margin30.1%
Operating margin1.8%
Net margin-9.3%
Revenue growth (YoY)+5.7%
Revenue growth (3-yr annual)+3.8%
EPS growth (YoY)-16.2%
FCF/share growth (YoY)-42.6%
Beta0.7
ExchangeNYSE
SectorHealthcare
IndustryMedical Instruments Supplies

BAX earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $0.60). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Oct 29, 2026 $0.58 $0.52 +11.5% $2.98B
Q2 2026 Jul 30, 2026 $0.56 $0.37 +51.4% $2.96B
Q1 2026 Apr 30, 2026 $0.36 $0.31 +16.1% $2.70B
Q4 2025 Feb 12, 2026 $0.44 $0.54 -18.5% $2.97B

BAX analyst price target

Median target $26.00 from 12 analysts, ranging $20.00 – $40.00.

Medical Instruments Supplies peers

TickerCompanyMarket capP/E
ISRG Intuitive Surgical $159.96B 41.8
BDX Becton, Dickinson $57.71B 16.1
MDLN Medline $52.17B 25.1
ALC Alcon $36.23B 23.0
RMD ResMed $33.10B 20.4
WST West Pharmaceutical Services $27.85B 43.5
SOLV Solventum $15.38B 12.8
COO Cooper Companies $11.86B 13.5
Explore live BAX data on Nama Insights →

Recent Congressional trades

Baxter International trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Lisa McClain House Sell $1,001 - $15,000 Nov 21, 2025
Lisa McClain House Buy $1,001 - $15,000 Nov 21, 2025
Lisa McClain House Buy $1,001 - $15,000 Oct 22, 2025
Lisa McClain House Sell $1,001 - $15,000 Sep 12, 2025
Lisa McClain House Buy $1,001 - $15,000 Aug 13, 2025
Rob Bresnahan House Buy $1,001 - $15,000 Jun 9, 2025
Debbie Wasserman Schultz House Buy $1,001 - $15,000 Nov 20, 2024
Earl Blumenauer House Buy $15,001 - $50,000 Aug 6, 2024
David A Perdue , Jr Senate Sell $15,001 - $50,000 —
David A Perdue , Jr Senate Sell $15,001 - $50,000 —
David A Perdue , Jr Senate Sell $1,001 - $15,000 —
David A Perdue , Jr Senate Sell $1,001 - $15,000 —

BAX FAQ

Is BAX a buy?
Nama's AI scorecard currently rates Baxter International Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BAX's P/E ratio?
Baxter International trades at a trailing price-to-earnings ratio of 13.3.
When does BAX report earnings?
Baxter International's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.60.
What is the BAX price target?
The median analyst price target from 12 analysts is $26.00, with a range of $20.00 – $40.00.
Is BAX Shariah compliant?
Nama's AAOIFI-style screen reads Baxter International as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does BAX pay a dividend?
Yes — Baxter International's dividend yield is 0.2%.

See more: Healthcare stocks →